Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Sitagliptin for Inpatient Hyperglycemia
NCT06187285Completed
- Sponsor
- Medanta
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Medanta. Primary endpoint: Mean blood glucose concentration at 7 days. Started Jan 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06187285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187285.